Gensight Biologics SA is a France-based company, which specializes in the clinical-stage biotechnology and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The Company, through I ts integrated development platform, combines a gene therapy-based approach with core technology platforms of mitochondrial targeting sequence and optogenetics. It focuses on development of therapies for severe retinal diseases with the goal of preserving or restoring vision in patients with sight-threatening ophthalmic diseases. The Company provides two development programs with products, such as GS010 which aims at treating rare mitochondrial genetic disease, and GS030 which technology makes cells responsive to light. The products are designed to be administered in a single treatment to each eye by intravitreal or subretinal injection.